Showing results (881-890 of 1,024) with videos related to

Sort By:
Pageof 103
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyEzra E W Cohen, Lee S Rosen, Everett E Vokes, et al.
The Journal of School Health|April 1, 2025
Understanding Free or Reduced-Price School Meal Stigma: A Qualitative Analysis of Parent PerspectivesLeah Elizabeth Chapman, Wendi Gosliner, Marlene B Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 TrialDavid S Hong, Michael Postow, Bartosz Chmielowski, et al.
Scientific Reports|April 11, 2018
Positive Surgical Margins in the 10 Most Common Solid CancersRyan K Orosco, Viridiana J Tapia, Joseph A Califano, et al.
Journal for Immunotherapy of Cancer|September 4, 2025
The spontaneous neoantigen-specific CD4+ T-cell response to a growing tumor is functionally and phenotypically diverseRyan Q Griswold, Spencer E Brightman, Karla Soria Zavala, et al.
Surgical Oncology|September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerationsDavid A Barrington, Ashley S Felix, Rieham Owda, et al.
Oral Oncology|November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrenceK J Harrington, E E W Cohen, D Soulières, et al.
Health Affairs Scholar|May 17, 2024
Parent perceptions of school meals and how perceptions differ by race and ethnicityMonica D Zuercher, Juliana F W Cohen, Punam Ohri-Vachaspati, et al.
Cancer Research|March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinomaTanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Oral Oncology|June 19, 2018
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinomaRenata Ferrarotto, William N William, Jennifer E Tseng, et al.
Pageof 103